For people with heart disease, taking semaglutide means about 1 in 12 will stop treatment because of stomach problems like nausea or diarrhea — much more common than with a dummy pill.

For adults with heart disease and obesity who don’t have diabetes, taking a weekly semaglutide shot (2.4 mg) leads to more than twice as many people stopping treatment because of side effects compared to those taking a dummy shot.

A weekly injection of semaglutide (2.4 mg) helps lower the risk of serious heart problems like heart attack, stroke, or heart-related death by 20% in people over 45 who have heart disease and are overweight, but don’t have diabetes, compared to a fake treatment.

In adults with type 2 diabetes and chronic kidney disease, taking a weekly 1.0 mg dose of semaglutide is associated with an 18% lower risk of major cardiovascular events compared to a placebo over approximately 3.4 years.

In obese adults without diabetes but with heart disease, weekly injections of semaglutide at 2.4 mg led to a higher rate of patients stopping treatment because of side effects compared to those receiving a placebo.

If you're obese and have heart disease but not diabetes, taking semaglutide might lower your chances of having a serious heart problem by 20%.